13F Holdings
中文EN

OGEN ORAGENICS INC

Pharmaceutical Preparations · NYSE · SEC CIK 1174940 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY11.8%
TTM EPS YoY-102.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-176.1%
ROA-120.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets66.7%
Debt / equity0.00x
Current ratio—
Interest coverage-547.81x

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-4.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue——$37,653$131,521$86,987
R&D expense$2.39M$4.11M$15.49M$10.07M$10.59M
SG&A expense$6.97M$6.44M$5.45M$4.48M$5.27M
Operating income-$9.36M-$10.56M-$20.90M-$14.42M-$15.77M
Interest expense$785,930$29,828$30,591$15,103$15,756
Pretax income-$9.98M-$10.57M-$20.66M-$14.29M-$15.71M
Income tax-$136,910————
Net income-$9.84M-$10.57M-$20.66M-$14.29M-$15.71M
EBITDA——-$20.88M-$14.38M-$15.73M
EPS (basic)-4.56-47.88-9.18-7.11-8.09
EPS (diluted)-4.56-47.88-9.18-7.11-0.14
Weighted avg. shares (diluted)2.16M220,7312.25M2.01M112.92M
Banking
Deposits———$17,940$17,940
Balance sheet
Cash & equivalents$4.40M$864,840$3.48M$11.43M$27.27M
Short-term investments$4.00M————
Current assets$10.07M$1.47M$3.87M$14.29M$27.71M
PP&E, net——$0$121,062$45,708
Total assets$10.07M$1.47M$4.97M$14.76M$28.23M
Current liabilities——$1.80M$1.60M$1.45M
Total liabilities$1.79M$1.68M$1.80M$1.75M$1.74M
Shareholders' equity$8.28M-$211,885$3.17M$13.01M$26.49M
Shares outstanding4.27M419,0033.08M2.02M2.00M
Cash flow statement
Operating cash flow-$9.25M-$8.60M-$7.29M-$15.23M-$13.47M
Capital expenditure———$127,519$43,876
Free cash flow———-$15.36M-$13.51M
Investing cash flow——-$936,284-$115,519-$43,876
Financing cash flow$16.78M$5.98M$283,880-$494,916$23.14M
Depreciation & amortization——$27,391$44,667$41,237
Stock-based compensation$642,364$516,049$1.02M$742,203$1.69M

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.